Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taking No Chances in Neuroprotection: Pharmos Applies a Precise Phase III Protocol

This article was originally published in Start Up

Executive Summary

Neuroprotection has been something of a clinical tar pit--many compounds have gone into the clinic but none have emerged. It's hard to know what's going on inside someone else's head, much less measure changes induced by any agent. Pharmos feels it has learned from the missteps of other companies, and so has structured a highly precise Phase III protocol to give its drug candidate dexanabinol the best chance at success.
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC090787

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel